Skip to content
DataLookout
Menu

Changes this week

Changes detected in the 7 days to Nov 21, 2026

  1. Minor: Subthreshold SCS or BMT Primary and study completion pushed from Aug 2026 to Dec 2026 Moens MaartenNot applicable NCT05169047
  2. Minor: Performance of Bioactive Bulk-Fill in Class II Restorations Primary completion pushed from Jun 30, 2027 to Nov 30, 2027 Bezmialem Vakif UniversityNot applicable NCT07547904
  3. Minor: Myofascial Exercise and Trigger Point Therapy for Non-Specific Low Back Pain Primary completion pushed from Oct 30, 2026 to Nov 30, 2026 National Yang Ming Chiao Tung UniversityNot applicable NCT07362420
  4. Minor: Transversalis Fascia Plane Block Versus Low-Dose Intrathecal Morphine for Open Inguinal Hernia Repair Primary completion pushed from Oct 23, 2026 to Dec 1, 2026 Hitit UniversityNot applicable NCT07695935
  5. Minor: Arterial Stiffness · Breast Cancer Primary and study completion dates pushed to Mar 1, 2027 Hacettepe UniversityNot applicable NCT07070778
  6. Minor: Exercise Intervention for Breast Cancer · Sarcopenia Primary and study completion pushed from May 30, 2027 to Aug 30, 2027 Capital Medical UniversityNot applicable NCT07732101
  7. Minor: Usability of a Chest-Strap Ambulatory ECG Monitor in Active Individuals in Comparison With a Traditional Ambulatory ECG Patch Monitor (MoMe ARC) Primary completion pushed from Feb 23, 2027 to Apr 23, 2027 Mayo ClinicNot specified NCT07772817
  8. Minor: RCT Study on the Effect of ETN on Live Birth Rate in DOR Patients Undergoing IVF-ET Primary completion pushed from Feb 1, 2031 to Apr 1, 2031 Huazhong University of Science and TechnologyNot applicable NCT07769684
  9. Minor: Efimosfermin Compared With Placebo · Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH) Trial sites expanded: 30 → 37 locations GlaxoSmithKlinePhase 3 NCT07701993
  10. Minor: Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) · Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Trial sites expanded: 133 → 138 locations SanofiPhase 3 NCT06290141
  11. Minor: GSK5784283 (Felcorekibart) Compared With Placebo · Moderate to Very Severe COPD (PERSIST COPD-1) Trial sites expanded: 7 → 11 locations GlaxoSmithKlinePhase 3 NCT07780669
  12. Minor: InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation Trial sites expanded: 121 → 293 locations GlaxoSmithKlinePhase 3 NCT07177339
  13. Minor: Lunsekimig Compared With Placebo · Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype Trial sites expanded: 314 → 322 locations SanofiPhase 3 NCT07190209
  14. Minor: Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec · Hemophilia A or B Respectively Trial sites expanded: 39 → 44 locations PfizerPhase 3 NCT05568719
  15. Minor: Intratumoral INT230-6 Compared to US Standard of Care · Soft Tissue Sarcomas (INVINCIBLE-3) Trial sites expanded: 17 → 20 locations Intensity Therapeutics, Inc.Phase 3 NCT06263231
  16. Minor: Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta Trial sites expanded: 4 → 9 locations AmgenPhase 3 NCT07366086
  17. Minor: Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04) Trial sites expanded: 11 → 18 locations Merck Sharp & Dohme LLCPhase 3 NCT07776691
  18. Minor: Lunsekimig · Chronic Obstructive Pulmonary Disease (COPD) Trial sites expanded: 8 → 16 locations SanofiPhase 3 NCT07793409
  19. Minor: EYE201/MK-8748 · Macular Degeneration (MK-8748-003) Trial sites expanded: 71 → 121 locations EyeBiotech Ltd.Phase 2/3 NCT07496567
  20. Minor: Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis (PEP) of Influenza Virus Infection in Chinese Participants Trial sites expanded: 8 → 20 locations Hoffmann-La RochePhase 3 NCT07827599
  21. Minor: SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) Trial sites expanded: 61 → 75 locations Nuvation Bio Inc.Phase 3 NCT05303519
  22. Minor: ALKS 2680 · Narcolepsy Type 2 Trial sites expanded: 44 → 61 locations Alkermes, Inc.Phase 3 NCT07502443
  23. Minor: EloraTZP · Obesity Without Type 2 Diabetes Trial sites expanded: 155 → 161 locations Eli Lilly and CompanyPhase 3 NCT07881432
  24. Minor: Sacituzumab Tirumotecan (Sac-TMT, MK-2870) · Breast Cancer (MK-2870-032) Trial sites expanded: 335 → 338 locations Merck Sharp & Dohme LLCPhase 3 NCT06966700
  25. Minor: Sacituzumab Tirumotecan (Sac-TMT, MK-2870) · Urothelial Cancer (MK-2870-031) Trial sites expanded: 111 → 117 locations Merck Sharp & Dohme LLCPhase 3 NCT07419295